Longboard Pharmaceuticals, Inc entered into a Non-Voting Common Stock Purchase Agreement and issued 2,850,000 shares of its non-voting common stock to the Investor at a purchase price of $21 per share, for aggregate gross proceeds of $59,850,000 on March 26, 2024. The transaction included participation from returning investor, Farallon Capital Management, L.L.C.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.03 USD | +20.19% |
|
+29.89% | +348.26% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+348.26% | 1.05B | |
+15.20% | 121B | |
+19.67% | 113B | |
+18.95% | 26.02B | |
-23.86% | 19.39B | |
-19.03% | 15.91B | |
-20.90% | 15.09B | |
-46.14% | 15.06B | |
+63.85% | 14.93B | |
+4.49% | 13.85B |
- Stock Market
- Equities
- LBPH Stock
- News Longboard Pharmaceuticals, Inc.
- Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding